logo-loader

Creo Medical under the eye of Proactive research analyst Daniel Appiah

Last updated: 12:07 04 Nov 2022 EDT, First published: 08:07 04 Nov 2022 EDT

Creo Medical Group PLC (AIM:CREO) is discussed by Proactive research analyst Daniel Appiah who talks Thomas Warner through his latest report.

Two licensing revenue deals this year will see Creo’s technology used in robotics-assisted laparoscopic (keyhole) surgery to enhance the effectiveness of procedures.

Creo's technology allows minimally invasive endoscopic technology and licensing can be a very important revenue stream in future, Appiah adds. #proactiveinvestors #creomedical

Click here to read the report

Alvopetro posts 86% net back margin as Q2 volumes jump 26% and Murucututu...

Alvopetro Energy Ltd (TSX-V:ALV, OTC:ALVOF, FRA:A6Y0) CEO Corey Ruttan tells Proactive's Stephen Gunnion that Q2 2026 sales volumes averaged 3,067 barrels of oil equivalent per day, up 26% year-on-year, with revenue of just over $19 million and funds flow from operations of $14.1...

22 hours, 57 minutes ago